| Symbol | ABUS |
|---|---|
| Name | ARBUTUS BIOPHARMA CORP |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 701 VETERANS CIRCLE, WARMINSTER, PA 18974 |
| Telephone | 604-419-3200 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001447028 |
| Description | None |
New Form SCHEDULE 13G - Arbutus Biopharma Corp <b>Filed:</b> 2026-09-04 <b>AccNo:</b> 0000921895-26-002494 <b>Size:</b> 31 KB
Read moreArbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
Read moreArbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
Read moreNew Form SC TO-C - Arbutus Biopharma Corp <b>Filed:</b> 2026-08-21 <b>AccNo:</b> 0001104659-26-099391 <b>Size:</b> 55 KB
Read moreNew Form SCHEDULE 13G/A - Arbutus Biopharma Corp <b>Filed:</b> 2026-08-12 <b>AccNo:</b> 0000895421-26-000222 <b>Size:</b> 12 KB
Read more(80% Positive) ARBUTUS BIOPHARMA CORP (ABUS) Reports Q3 2026 Financial Results
Read moreArbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read more(99% Neutral) ARBUTUS BIOPHARMA CORP (ABUS) Announces Business Combination
Read moreArbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Read more